Orum Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/10/26	₩21,150.00	-9.42%	507,710
01/10/26	₩23,350.00	+5.42%	385,381
30/09/26	₩22,150.00	-1.56%	371,322
29/09/26	₩22,500.00	-7.22%	713,857
28/09/26	₩24,250.00	-3.00%	375,622

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 01/10/2026			5-day change	1st Jan Change
23,350.00 ^KRW	+5.42%		-6.60%	-80.54%

08-22	Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate	CI
07-15	Alert wrongly tagged to Orum Therapeutics withdrawn	RE

Market Cap	508B 373M 331M 310M 282M 531M 35.88B 538M 3.74B 1.45B 18.27B 1.4B 1.37B 58.69B	P/E 2024 *	-	P/E 2025	-59.5x
Enterprise Value	401B 294M 261M 244M 223M 419M 28.31B 425M 2.96B 1.14B 14.42B 1.1B 1.08B 46.32B	EV / Sales 2024 *	-	EV / Sales 2025	103,580x
Free-Float	84.18%	Yield 2024 *	-	Yield 2025	-

08-22	Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate	CI
07-15	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
04-17	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI
04-13	Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors	CI
01-15	Orum Therapeutics, Inc. announced that it has received KRW 24.999873175 billion in funding from a group of investors	CI
01-04	Orum Therapeutics Appoints Chad May as Chief Scientific Officer	CI
12-18	Orum Therapeutics, Inc. announced that it expects to receive KRW 24.999873175 billion in funding from a group of investors	CI
11-03	Orum Therapeutics Announces Presentation of Preclinical Data for Orm-1153 At the 2025 American Society of Hematology Annual Meeting	CI
15/10/25	Orum Therapeutics Appoints Dorin Toader as Head of Platform Technology	CI
23/06/25	Orum Therapeutics, Inc.(KOSDAQ:A475830) added to S&P Global BMI Index	CI
07/02/25	Orum Therapeutics, Inc. has completed an IPO in the amount of KRW 50 billion.	CI
16/07/24	Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex Pharmaceuticals for the Use of Orum's TPD2 Technology to Develop Novel Degrader-Antibody Conjugates	CI

08-23	Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate	AQ
12-19	Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases	AQ
15/10/25	Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orums Degrader-Antibody Conjugate Payload Platforms and Expand TPD Therapeutic Applications	AQ

Orum Therapeutics, Inc. Share Price

Stocks

A475830

KR7475830006

Biotechnology & Medical Research

Valuation: Orum Therapeutics, Inc.

Chart: Orum Therapeutics, Inc.

Latest news: Orum Therapeutics, Inc.

Press Releases: Orum Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Orum Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 day	+5.42%
1 week	-6.60%
Current month	+5.42%
1 month	-60.56%
3 months	-59.60%
6 months	-73.01%
Current year	-80.54%

1 week	20,850	26,000
1 month	20,850	57,900
Current year	20,850	146,600
1 year	20,850	146,600
3 years	15,950	146,600
5 years	15,950	146,600
10 years	15,950	146,600

Manager	Title	Age	Since
Seung-Ju Lee CEO	Chief Executive Officer	52	16/08/2016
In-Tae Jeong DFI	Director of Finance/CFO	44	22/10/2023
Chad May CTO	Chief Tech/Sci/R&D Officer	-	04/01/2026

Director	Title	Age	Since
Seung-Ju Lee BRD	Director/Board Member	52	16/08/2016
In-Tae Jeong BRD	Director/Board Member	44	22/10/2023
Un-Nam Park BRD	Director/Board Member	55	31/03/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/02/25	Seung-Ju Lee	Free	Founder	3,388,000	-
21/02/25	In-Tae Jeong	Free	Chief Financial Officer	10,000	-
21/02/25	Un-Nam Park	Free	Director	60,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORUM THERAPEUTICS, INC.	+5.42%	-6.60%	-31.22%	-	373M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.41B
ARGENX SE	-3.02%	-3.41%	+22.07%	+74.82%	59.26B
LONZA GROUP AG	+1.21%	-0.70%	+4.20%	+34.41%	47.14B
IQVIA HOLDINGS INC.	-0.43%	-3.77%	+27.32%	+34.19%	42.91B
REVOLUTION MEDICINES, INC.	-0.29%	+0.68%	+351.58%	+688.57%	44.13B
BEONE MEDICINES AG	-2.00%	-2.14%	+2.31%	+97.84%	40.79B
CELLTRION, INC.	+3.32%	+3.49%	+10.10%	+51.23%	30.77B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+22.72%	29.31B
INSMED INCORPORATED	+0.12%	-8.18%	-29.19%	+326.47%	23.71B
Average	+0.55%	-1.13%	+43.62%	+158.27%	39.28B
Weighted average by Cap.	+0.23%	-0.32%	+57.12%	+150.07%

	2024	2025
Net sales	20.91B 15.34M 13.62M 12.74M 11.61M 21.86M 1.48B 22.16M 154M 59.66M 752M 57.59M 56.34M 2.42B	23.56M 17.29K 15.36K 14.36K 13.09K 24.64K 1.66M 24.98K 174K 67.25K 848K 64.91K 63.5K 2.72M
Net income	-5.74B -4.21M -3.74M -3.5M -3.19M -6M -405M -6.08M -42.32M -16.38M -207M -15.81M -15.47M -663M	-41.97B -30.79M -27.35M -25.58M -23.31M -43.88M -2.96B -44.48M -309M -120M -1.51B -116M -113M -4.85B
Net Debt	-90.47B -66.38M -58.96M -55.13M -50.24M -94.59M -6.39B -95.89M -667M -258M -3.25B -249M -244M -10.45B	-107B -78.58M -69.8M -65.27M -59.48M -112M -7.57B -114M -790M -306M -3.85B -295M -289M -12.38B